Anti-Cd20/Cd30-Car-T Cells
Relapsed/Refractory Lymphoma
Affiliated Hospital of Nantong UniversityCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Relapsed/Refractory Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
hx009 Hangzhou Hanx Biopharmaceuticals, Ltd. | Phase 1/2 | CCC |
tqb2618 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1/2 | CCC |
f527 Shandong New Time Pharmaceutical Co., LTD | Phase 1 | CC |
Ovv-01 Beijing Boren Hospital | Early Phase 1 | C |
ibr900 cell Beijing Boren Hospital | Early Phase 1 | C |
Same molecule, other indications
Anti-Cd20/Cd30-Car-T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →